Concepedia

Thomas A. Hardy

TA

Statistics

Publications

39

Citations

2K

H-Index

24

Active since

1977

Affiliations

Eli Lilly (United States)(Current)

James Cook University

Atlanta Diabetes Associates

Indiana University – Purdue University Indianapolis

Indiana University School of Medicine

Thomas A. Hardy is an author at Eli Lilly (United States) specializing in medicine, diabetes mellitus, and pharmacology.

Publications per year

1977–2021

39

Publications

39

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof Kazda, Ying Ding, Ronan P. Kelly et al. · Diabetes Care · 2015 · 215 citations · Full text

, , +17

Field study of wave attenuation on an offshore coral reef

Thomas A. Hardy, Ian R. Young · Journal of Geophysical Research Atmospheres · 1996 · 178 citations

, , +13

Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Cristina B. Guzmán, Xiaotian Michelle Zhang, Rong Liu et al. · Diabetes Obesity and Metabolism · 2017 · 165 citations

, , +17

Mathematical models of diabetes progression

Andrea De Gaetano, Thomas A. Hardy, Benoît Beck et al. · American Journal of Physiology-Endocrinology and Metabolism · 2008 · 113 citations

, , +17

The Metabolic Syndrome in Patients With Severe Mental Illnesses

Patrick A. Toalson, Saeeduddin Ahmed, Thomas A. Hardy et al. · The Primary Care Companion For CNS Disorders · 2004 · 110 citations · Full text

, , +11

1–5 of 39